Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Demand For Robotic Surgery Drives Intuitive Surgical’s Revenues Up 21% in Q2

Executive Summary

Intuitive Surgical reported on 18 July that worldwide da Vinci procedures were up about 17% in the second quarter of 2019 compared to the same period of 2018. While the US still accounts for the majority of Intuitive’s revenue, procedure volume outside the US is growing faster, especially in Asia.

You may also be interested in...



Analysts See Threat To Intuitive Surgical From Third-Party Repair Businesses

Intuitive Surgical’s da Vinci robotic-assisted surgery system is facing a new competitor that may be harder to beat than the robotic-assisted surgery systems created by other companies. According to analysts, a growing number of hospitals will begin to use repaired da Vinci instruments supplied by third-parties, which could potentially impede the growth of Intuitive’s business.

Medtronic Introduces Hugo To Rival Intuitive's Robotic Surgery System

The company unveiled its new modular robotic surgery system for minimally invasive surgery at a special event in Hartford, CT. Medtronic expects the new system to earn a CE mark by early 2021 and FDA approval by the end of 2021.

Brain Therapies Leads Medtronic’s Growth In First Quarter Of Fiscal 2020

The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT125395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel